Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release)
Panorama uses free-floating fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with . . .
→ Read full post: Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test
February 20, 2013 source: the original post by Ed Silverman appeared in Pharmalot
As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But this poses challenges, of course, and Ted Driscoll, who heads the digital healthcare team at . . .
→ Read full post: Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data
September 9, 2011 source: originally published in the San Francisco Business Times
Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.
Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.
A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby . . .
→ Read full post: Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test
July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product
November 1, 2010 source: Gene Security Network (download the pdf press release)
REDWOOD CITY, CA – November 1, 2010 – Gene Security Network, Inc. (GSN) today announced the closing of its $12M Series C financing. The financing round was led by Sequoia Capital and included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.
GSN is a molecular diagnostics company using data informatics to enhance genetic testing of DNA. . . .
→ Read full post: Gene Security Network Completes Funding to Expand Into New DNA Testing Markets
August 10, 2010 source: Send2Press Newswire DAVIS, Calif., Aug. 10 (SEND2PRESS NEWSWIRE) — California IVF: Davis Fertility Center, Inc. (californiaivf.com), working in conjunction with Gene Security Network (genesecurity.net) leads the field in bringing a new test to patients that combines the detection of single-gene genetic disorders with a 24 chromosome screening. Using Gene Security Network’s Parental Support™ technology, at-risk couples undergoing in vitro fertilization can now test developing embryos for a larger number . . .
→ Read full post: Fertility Patients Can Now Use One Screening for Multiple Types of Genetic Diseases Before Pregnancy